2016 American Transplant Congress
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.
Introduction: Role of IgG antibodies against donor human leucocyte antigens (HLA) is established in renal transplant monitoring. Role of IgM donor HLA specific antibodies (DSA)…2016 American Transplant Congress
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…2016 American Transplant Congress
The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplantation in HLA-sensitized patients. ADCC is one of the primary mechanisms for ABMR. IdeS cleaves…2016 American Transplant Congress
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.
1Pathology, Emory University, Atlanta, GA; 2Emory Transplant Center, Emory University, Atlanta, GA.
AIM: On 12/4/2014, the OPTN implemented a new KAS for deceased donor(DD) transplants which, among many changes, increased priority for highly sensitized (HS) candidates (cPRA>98%).…2016 American Transplant Congress
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
Introduction: Angiotensin II type I receptor antibody (AT1R Ab) is a target for non-HLA antibodies. AT1R ab exert direct effects on endothelial and vascular smooth…2016 American Transplant Congress
Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.
Introduction: Pre-transplant IgG antibody screening is common due to its established role of predicting rejection and graft survival; the role of pre-formed IgM human leukocyte…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…2015 American Transplant Congress
Comparison of One-Year Outcomes in High Risk Kidney Transplantation: ABO Incompatible and DSA Positive/CDC-AHG Negative
Back ground: Both donor specific anti-HLA antibody (DSA) and anti-ABO are the major barriers in kidney transplantation. We evaluated the outcomes of desensitization protocols in…2015 American Transplant Congress
Etiology, Incidence and Outcomes of the Highly Sensitized Kidney Transplant Patient
University of Wisconsin, Madison, WI.
Background: Sensitization to HLA antigens is a major barrier to kidney transplantation. We sought to determine the etiology, incidence and outcomes of kidney transplants performed…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- Next Page »